CTX-213

N/A

Report date: 2025/06/30 16:21:49

Base Information

Drug NameCTX-213

Drug Alias NameDeviceless approach for Type 1 diabetes mellitusUnencapsulated investigational allogeneic, gene-edited, immune-evasive, stem cell-derived beta-cell replacement therapyCTX-213

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy

Mechanisms of ActionPancreatic beta cell replacements

TargetsNot applicable

Therapy Area/IndicationsDiabetes Mellitus, Type 1

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCrispr Therapeutics Ag

China Registration ClassN/A

Develop Information

Active CompaniesCrispr Therapeutics Ag

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 1

Inactive IndicationsN/A

Other Information

ATC CodeN/A